42923-79-5

Usage

Uses

Used in Pharmaceutical Research and Development:
7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is used as a chemical building block for the synthesis of various pharmaceuticals and organic compounds. Its nitro group provides versatility in the creation of bioactive molecules, which can be further developed into potential drugs.
Used in Drug Synthesis for Neurological Disorders:
In the field of medicinal chemistry, 7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is utilized as a precursor in the development of drugs that target neurological disorders. Its structural properties allow for the design of molecules that can interact with specific biological targets, offering new therapeutic options for the treatment of such conditions.
Used in Organic Chemistry:
7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is also used in organic chemistry for the synthesis of a variety of organic compounds. Its reactivity and functional group chemistry enable the creation of diverse molecules with potential applications in various industries.
Used in Environmental and Health Safety Research:
Given the potential hazards of nitro compounds, 7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is also used in research aimed at understanding and mitigating the environmental and health risks associated with its use. This includes the development of safer handling procedures and the exploration of less toxic alternatives in pharmaceutical synthesis.

InChI:InChI=1/C9H10N2O2/c12-11(13)9-2-1-7-3-4-10-6-8(7)5-9/h1-2,5,10H,3-4,6H2

Upstream product

• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 181514-37-4 2,2,2-trifluoro-1-(7-nitro-3,4-dihydroisoquinolin-2(1H)-yl)-ethan-1-one 
• 14028-67-2 N-acetyl-1,2,3,4-tetrahydroisoquinoline 
• 99365-69-2 7-nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 55649-51-9 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline 
• 458-85-5 2,2,2-trifluoro-N-(2-phenylethyl)acetamide 
• 64-04-0 phenethylamine 
• 22245-96-1 7-nitro-3,4-dihydro-2H-isoquinolin-1-one 
• 24954-63-0 2,2,2-Trifluoro-N-(2-(4-nitrophenyl)ethyl)acetamide 
• 99365-63-6 1-(7-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one 

Downstream Products

• 13058-73-6 7-nitroisoquinoline 
• 855645-98-6 2-benzoyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline 
• 81885-67-8 2-acetyl-7-amino-1,2,3,4-tetrahydro-isoquinoline 
• 791040-11-4 8-nitro-1,2,3,4-tetrahydroisoquinoline 
• 186390-77-2 6-nitro-1,2,3,4-tetrahydro-isoquinoline 
• 174648-93-2 N-acetyl-7-amino-6-nitro-1,2,3,4-tetrahydroisoquinoline 
• 14097-40-6 7-amino-2-methyl-1,2,3,4-tetrahydroisoquinoline 
• 84017-98-1 N-(2-methyl-1,2,3,4-tetrahydro-[7]isoquinolyl)-benzamide 

Relevant academic research and scientific papers

CuI-catalyzed C1-alkynylation of tetrahydroisoquinolines (THIQs) by A 3 reaction with tunable iminium ions

A CuI-catalyzed A3 (amines, aldehydes and alkynes) reaction of tetrahydroisoquinolines (THIQs), aldehydes, and alkynes to give C1-alkynylated THIQ products (endo-yne-THIQs) was developed. This redox neutral C1-alkynylation of THIQs, which was c

Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents

Among several potential applications, sigma receptors (σRs) can be used as neuroprotective agents, antiamnesic, antipsychotics and against other neurodegenerative disorders. On the other hands, antagonists of the GluN2b-subunit-containing-N-methyl-D-aspar

Development of versatile and potent monoquaternary reactivators of acetylcholinesterase

To date, the only treatments developed for poisoning by organophosphorus compounds, the most toxic chemical weapons of mass destruction, have exhibited limited efficacy and versatility. The available causal antidotes are based on reactivation of the enzyme acetylcholinesterase (AChE), which is rapidly and pseudo-irreversibly inhibited by these agents. In this study, we developed a novel series of monoquaternary reactivators combining permanently charged moieties tethered to position 6- of 3-hydroxypyridine-2-aldoxime reactivating subunit. Highlighted representatives (21, 24, and 27; also coded as K1371, K1374, and K1375, respectively) that contained 1-phenylisoquinolinium, 7-amino-1-phenylisoquinolinium and 4-carbamoylpyridinium moieties?as peripheral anionic site ligands, respectively, showed efficacy superior or comparable to that of the clinically used standards. More importantly, these reactivators exhibited wide-spectrum efficacy and were minutely investigated via determination of their reactivation kinetics in parallel with molecular dynamics simulations to study their mechanisms of reactivation of the tabun-inhibited AChE conjugate. To further confirm the potential applicability of these candidates, a mouse in vivo assay was conducted. While K1375 had the lowest acute toxicity and the most suitable pharmacokinetic profile, the oxime K1374 with delayed elimination half-life was the most effective in ameliorating the signs of tabun toxicity. Moreover, both in vitro and in vivo, the versatility of the agents was substantially superior to that of clinically used standards. Their high efficacy and broad-spectrum capability make K1374 and K1375 promising candidates that should be further investigated for their potential as nerve agents and insecticide antidotes.

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure-activity relationship though cyclization modification based on previously reported compound 18e led to the discovery of the superior derivative 13ac. Compound 13ac showed excellent potency on JAK2 kinase, SET-2, and Ba/F3V617F cells (high expression of JAK2V617F mutation) with IC50 values of 3, 11.7, and 41 nM, respectively. Further mechanistic studies demonstrated that compound 13ac could downregulate the phosphorylation of downstream proteins of JAK2 kinase in cells. Compound 13ac also showed good selectivity in kinase scanning and potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model. Moreover, 13ac significantly ameliorated the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib.

1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS

The present invention relates to compounds of formula (I) : and pharmaceutically acceptable salts thereof, wherein R1and R2 are various ring systems. The invention also relates to pharmaceutical compositions comprising these compound

Electron-donating para-methoxy converts a benzamide-isoquinoline derivative into a highly Sigma-2 receptor selective ligand

The sigma-2 (σ2) receptor has been suggested to be a promising target for pharmacological interventions to curb tumor progression. Development of σ2-specific ligands, however, has been hindered by lack of understanding of molecular determinants that under

In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones

A series of 1,7-diaminoisoquinolinamines, that are expected to mediate antimalarial activity by the same mechanism employed by the chalcones, were produced. Six 7-benzylamino-1-isoquinolinamines were found to be submicromolar inhibitors in vitro of drug-r